Roivant Executive and Leadership Team

Matthew Gline, the Chief Executive Officer at Roivant, directs the company's overarching strategy and operational execution. Overseeing the completion of late-stage drug candidates, Gline ensures alignment with Roivant's mission to deliver innovative healthcare technologies. This leadership role involves guiding the organization's expansion and fostering a culture of scientific rigor and patient-centricity. By driving strategic partnerships and resource allocation, Matthew Gline significantly impacts the company's ability to bring novel therapies to market. Gline's focus remains on optimizing the development pipeline and maximizing the therapeutic potential of Roivant's portfolio. The Chief Executive Officer's vision shapes the company's direction, ensuring sustained growth and market leadership in the biopharmaceutical sector.

Stephanie Griffin, the Chief Operating Officer (Roivant Platforms) at Roivant, directs the operational execution and scaling of Roivant's platform capabilities. Overseeing the efficient delivery of healthcare technologies and the completion of drug development programs, Griffin ensures seamless integration and optimal performance across all platform functions. This leadership position involves managing complex project timelines and resource allocation to accelerate therapeutic advancements. By driving operational excellence, Stephanie Griffin enhances Roivant's capacity to bring innovative solutions to patients. Griffin's focus is on optimizing internal processes and fostering cross-functional collaboration to maximize the impact of Roivant's late-stage drug candidates. The Chief Operating Officer (Roivant Platforms) ensures the robust and scalable delivery of Roivant's core business model.

Eric Venker, the President at Roivant, drives strategic initiatives and corporate development to advance the company's mission. Overseeing key growth opportunities and fostering strategic partnerships, Venker ensures Roivant's continued leadership in delivering innovative healthcare technologies. This position involves guiding the expansion of the company's portfolio and enhancing its capacity to complete late-stage drug candidates. By championing new ventures and optimizing resource deployment, Eric Venker significantly contributes to Roivant's market impact. Venker's leadership focuses on identifying and capitalizing on opportunities that align with Roivant's commitment to patient well-being. The President's role is central to shaping Roivant's future trajectory and solidifying its position as a leader in biopharmaceutical innovation.

Ian Rosenblum, the Chief Information Officer at Roivant, architects the company's technology infrastructure and digital transformation initiatives. Overseeing all aspects of information systems, Rosenblum ensures robust data security and efficient operational workflows critical for drug development and healthcare technology delivery. This role involves managing the integration of advanced technological solutions to support Roivant's research and development efforts. By driving innovation in data analytics and digital platforms, Ian Rosenblum enhances the company's capacity to complete late-stage drug candidates. Rosenblum's strategic direction supports seamless collaboration across Roivant's diverse operations, enabling faster decision-making and improved project outcomes. The Chief Information Officer's leadership ensures Roivant maintains a competitive edge through cutting-edge technological capabilities.

Deya Corzo, the Chief Medical Officer, -Residence at Roivant, provides critical medical and scientific leadership for the company's drug development pipeline. Overseeing clinical strategy and execution, Corzo ensures that late-stage drug candidates meet rigorous scientific and regulatory standards. This role involves guiding the design and implementation of clinical trials, focusing on delivering innovative healthcare technologies to patients. By leveraging extensive medical expertise, Deya Corzo drives the advancement of promising therapies through critical development phases. Corzo's insights are instrumental in shaping the clinical narrative and maximizing the therapeutic potential of Roivant's portfolio. The Chief Medical Officer, -Residence ensures that Roivant's scientific endeavors are aligned with patient needs and global health priorities.